Ultragenyx Pharmaceutical Long Term Debt

As of the most recent data (June 2026), RARE shows a long-term debt of $0. That compares with $810M in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RARE's long-term debt is now $0 (was $810M) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Ultragenyx Pharmaceutical is outperforming or lagging.

Tracking RARE's long-term debt over time shows whether Ultragenyx Pharmaceutical is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $810M in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Ultragenyx Pharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.

Ultragenyx Pharmaceutical's long-term debt is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.